NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 130 filers reported holding NURIX THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $137,825 | +622.4% | 6,604 | +408.8% | 0.00% | – |
Q1 2024 | $19,080 | -92.2% | 1,298 | -94.5% | 0.00% | -100.0% |
Q4 2023 | $243,604 | +3390.0% | 23,605 | +2558.2% | 0.00% | – |
Q3 2023 | $6,980 | -73.4% | 888 | -66.2% | 0.00% | -100.0% |
Q2 2023 | $26,214 | +26378.8% | 2,624 | -76.4% | 0.00% | -66.7% |
Q1 2023 | $99 | +1137.5% | 11,104 | +1488.6% | 0.00% | – |
Q4 2022 | $8 | -100.0% | 699 | -93.0% | 0.00% | -100.0% |
Q3 2022 | $131,000 | +129.8% | 10,035 | +121.6% | 0.00% | +100.0% |
Q2 2022 | $57,000 | +90.0% | 4,529 | +113.0% | 0.00% | – |
Q1 2022 | $30,000 | -77.9% | 2,126 | -54.6% | 0.00% | -100.0% |
Q4 2021 | $136,000 | +65.9% | 4,685 | +71.3% | 0.00% | 0.0% |
Q3 2021 | $82,000 | +6.5% | 2,735 | -6.0% | 0.00% | 0.0% |
Q2 2021 | $77,000 | -31.2% | 2,910 | -19.1% | 0.00% | 0.0% |
Q1 2021 | $112,000 | +30.2% | 3,596 | +38.2% | 0.00% | -33.3% |
Q4 2020 | $86,000 | +38.7% | 2,602 | +45.5% | 0.00% | +200.0% |
Q3 2020 | $62,000 | – | 1,788 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP III, LLC | 3,422,549 | $90,800,000 | 15.85% |
Ponoi II Management, LLC | 686,274 | $18,207,000 | 14.76% |
Ponoi Management, LLC | 686,274 | $18,207,000 | 10.12% |
Foresite Capital Management V, LLC | 451,522 | $11,979,000 | 4.71% |
Foresite Capital Management IV, LLC | 1,205,798 | $31,990,000 | 4.32% |
Bain Capital Life Sciences Investors, LLC | 1,284,314 | $34,073,000 | 2.23% |
EcoR1 Capital, LLC | 1,967,950 | $52,210,000 | 1.95% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $15,155,000 | 1.93% |
DAFNA Capital Management LLC | 306,320 | $8,127,000 | 1.70% |
Euclidean Capital LLC | 154,426 | $4,097,000 | 1.33% |